“It’s great to be able to work on Rousselot’s novel biomedical solutions and highest quality gelatins and collagens at such an early stage of our existence,” said SBMC CEO Jan Rietsema. “Supporting Rousselot in the development of validated solutions will boost building up our knowledge, expertise and facility services. For us, this MUO is also a recognition of SBMC’s network of collaborative partners that can potentially engage with Rousselot.”
“We are delighted with this new collaboration, which gives Rousselot access to SBMC’s expert knowledge in regenerative medicine and biomaterials and also offers exciting opportunities to connect and collaborate with its unique network of leading researchers, entrepreneurs and companies,” said Mieke Philipsen, Rousselot Chief Financial Officer. “Through this MOU, we intend to accelerate use of Rousselot’s biomedical gelatins in advanced healthcare solutions, furthering our mission to improve lives while striving to become the leading gelatin- and collagen-based solution provider in the biomedical field."